Clinical Trial Update: High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating whether a high-dose trivalent influenza vaccine can induce an immune response in patients with central nervous system neoplasms; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasms

Drugs mentioned

• High-dose trivalent influenza vaccine (High-dose trivalent inactivated influenza vaccine)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Central Nervous System Neoplasm | Phase 1 | Status: COMPLETED